Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin
- PMID: 26675382
- PMCID: PMC4670734
- DOI: 10.1002/jcsm.12063
Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin
Abstract
A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.
References
-
- Argiles JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11:229–230. - PubMed
-
- Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14:542–559. - PubMed
-
- von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014;15:866–872. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
